SEC Form SC 13G filed by Liquidia Corporation

5/5/23 11:52:59 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $LQDA alert in real time by email

SC 13G 1 us53635d2027_050423.txt us53635d2027_050423.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) LIQUIDIA CORP -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 53635D202 -------------------------------------------------------- (CUSIP Number) April 30, 2023 -------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 53635D202 (1)Names of reporting persons. BlackRock, Inc. (2) Check the appropriate box if a member of a group (a) [ ] (b) [X] (3) SEC use only (4) Citizenship or place of organization Delaware Number of shares beneficially owned by each reporting person with: (5) Sole voting power 3159489 (6) Shared voting power 0 (7) Sole dispositive power 3232051 (8) Shared dispositive power 0 (9) Aggregate amount beneficially owned by each reporting person 3232051 (10) Check if the aggregate amount in Row (9) excludes certain shares (11) Percent of class represented by amount in Row 9 4.99% (12) Type of reporting person HC Item 1. Item 1(a) Name of issuer: ----------------------------------------------------------------------- LIQUIDIA CORP Item 1(b) Address of issuer's principal executive offices: ----------------------------------------------------------------------- 419 DAVIS DRIVE, SUITE 100 MORRISVILLE NC 27560 Item 2. 2(a) Name of person filing: ---------------------------------------------------------------------- BlackRock, Inc. 2(b) Address or principal business office or, if none, residence: ----------------------------------------------------------------------- BlackRock, Inc. 50 Hudson Yards New York, NY 10001 2(c) Citizenship: -------------------------------------------------------------------- See Item 4 of Cover Page 2(d) Title of class of securities: ------------------------------------------------------------------- Common Stock 2(e) CUSIP No.: See Cover Page Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a: [ ] Broker or dealer registered under Section 15 of the Act; [ ] Bank as defined in Section 3(a)(6) of the Act; [ ] Insurance company as defined in Section 3(a)(19) of the Act; [ ] Investment company registered under Section 8 of the Investment Company Act of 1940; [ ] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); [ ] An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); [X] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G); [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940; [ ] A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J); [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: Item 4. Ownership Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. Amount beneficially owned: 3232051 Percent of class 4.99% Number of shares as to which such person has: Sole power to vote or to direct the vote 3159489 Shared power to vote or to direct the vote 0 Sole power to dispose or to direct the disposition of 3232051 Shared power to dispose or to direct the disposition of 0 Item 5. Ownership of 5 Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [ X ]. Item 6. Ownership of More than 5 Percent on Behalf of Another Person [ N/A ] Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. See Exhibit A Item 8. Identification and Classification of Members of the Group If a group has filed this schedule pursuant to Rule 13d-1(b)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identity of each member of the group. Item 9. Notice of Dissolution of Group Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5. Item 10. Certifications By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: May 4, 2023 BlackRock, Inc. Signature: Spencer Fleming ------------------------------------------- Name/Title Attorney-In-Fact The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature. Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001). Exhibit A Subsidiary BlackRock Advisors, LLC Aperio Group, LLC BlackRock Asset Management Canada Limited BlackRock Fund Advisors BlackRock Institutional Trust Company, National Association BlackRock Financial Management, Inc. BlackRock Investment Management, LLC *Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Exhibit B POWER OF ATTORNEY The undersigned, BlackRock, Inc., a corporation duly organized under the laws of the State of Delaware, United States (the "Company"), does hereby make, constitute and appoint each of Eric Andruczyk, Richard Cundiff, R. Andrew Dickson, III, Spencer Fleming, Daniel Goldmintz, Laura Hildner, Elizabeth Kogut, David Maryles, Christopher Meade, Una Neary, Charles Park, Daniel Riemer, David Rothenberg and Brenda Schulz, acting severally, as its true and lawful attorneys-in-fact, for the purpose of, from time to time, executing, in its name and on its behalf and on behalf of its direct and indirect subsidiaries, any and all documents, certificates, instruments, statements, filings, agreements and amendments (collectively, "documents") determined by such person to be necessary or appropriate to comply with ownership or control-person reporting requirements imposed by any United States or non-United States governmental or regulatory authority, including, without limitation, Schedules 13D and 13G and Forms 3, 4, 5, 13F and 13H and any amendments to any of the foregoing as may be required to be filed with the Securities and Exchange Commission, and delivering, furnishing or filing any such documents with the appropriate governmental or regulatory authority or other person, and giving and granting to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully and to all intents and purposes as the Company and/or its direct and indirect subsidiaries, as applicable, might or could do if personally present by one of its authorized signatories, hereby ratifying and confirming all that said attorney-in-fact shall lawfully do or cause to be done by virtue hereof. Any such determination by an attorney-in-fact named herein shall be conclusively evidenced by such person's execution, delivery, furnishing or filing of the applicable document. This power of attorney shall expressly revoke the power of attorney dated 2nd day of January, 2019 in respect of the subject matter hereof, shall be valid from the date hereof and shall remain in full force and effect until either revoked in writing by the Company, or, in respect of any attorney-in-fact named herein, until such person ceases to be an employee of the Company or one of its affiliates. IN WITNESS WHEREOF, the undersigned has caused this power of attorney to be executed as of this 30th day of April, 2023. BlackRock, Inc. By: /s/ R. Andrew Dickson, III Name: R. Andrew Dickson, III Title: Corporate Secretary

Get the next $LQDA alert in real time by email

Recent Analyst Ratings for

$LQDA

Date	Price Target	Rating	Analyst
8/15/2025	$43.00	Buy	Jefferies
5/19/2025	$13.00	Perform → Underperform	Oppenheimer
12/20/2024	$20.00	Overweight	Wells Fargo
10/16/2024		Sector Outperform	Scotiabank
8/19/2024		Outperform → Strong Buy	Raymond James
8/16/2024	$27.00	Outperform	Raymond James
6/25/2024		Perform	Oppenheimer
1/5/2024	$18.00 → $28.00	Buy	Needham

More analyst ratings

SEC Form SC 13G filed by Liquidia Corporation

5/5/23 11:52:59 AM ET

$LQDA

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $LQDA alert in real time by email

Recent Analyst Ratings for

$LQDA

Date	Price Target	Rating	Analyst
8/15/2025	$43.00	Buy	Jefferies
5/19/2025	$13.00	Perform → Underperform	Oppenheimer
12/20/2024	$20.00	Overweight	Wells Fargo
10/16/2024		Sector Outperform	Scotiabank
8/19/2024		Outperform → Strong Buy	Raymond James
8/16/2024	$27.00	Outperform	Raymond James
6/25/2024		Perform	Oppenheimer
1/5/2024	$18.00 → $28.00	Buy	Needham

More analyst ratings

SEC Form SC 13G filed by Liquidia Corporation

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$LQDA

SEC Form SC 13G filed by Liquidia Corporation

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$LQDA

$LQDA
Insider Trading

CFO and COO Kaseta Michael sold $600,132 worth of shares (30,000 units at $20.00), decreasing direct ownership by 7% to 376,412 units (SEC Form 4)

Chief Business Officer Adair Jason sold $8,871 worth of shares (454 units at $19.54), decreasing direct ownership by 0.23% to 193,180 units (SEC Form 4)

Chief Accounting Officer Boyle Dana sold $20,771 worth of shares (1,063 units at $19.54), decreasing direct ownership by 0.57% to 186,105 units (SEC Form 4)

$LQDA
Leadership Updates

Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors

Emergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of Directors

Liquidia Corporation Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

$LQDA
Insider Purchases

Director Manning Paul B bought $2,999,994 worth of shares (337,078 units at $8.90) (SEC Form 4)

Director Caligan Partners Lp disposed of 3,440,948 shares, sold $1,426,500 worth of shares (150,000 units at $9.51) and bought $1,426,500 worth of shares (150,000 units at $9.51) (SEC Form 4)

Jeffs Roger bought $1,000,001 worth of shares (139,665 units at $7.16), increasing direct ownership by 28% to 640,805 units (SEC Form 4)

$LQDA
Financials

Liquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Liquidia Corporation to Report Second Quarter 2025 Financial Results on August 12, 2025

Liquidia Corporation to Report First Quarter 2025 Financial Results on May 8, 2025

$LQDA
Press Releases

Liquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Liquidia Corporation to Report Second Quarter 2025 Financial Results on August 12, 2025

Liquidia Receives $50 Million from Healthcare Royalty (HCRx) Following First Commercial Sale of YUTREPIA™

$LQDA
SEC Filings

SEC Form 10-Q filed by Liquidia Corporation

Liquidia Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 144 filed by Liquidia Corporation

$LQDA
Analyst Ratings

Jefferies resumed coverage on Liquidia Technologies with a new price target

Liquidia Technologies downgraded by Oppenheimer with a new price target

Wells Fargo initiated coverage on Liquidia Technologies with a new price target

$LQDA
FDA approvals

FDA Tentative Approval for YUTREPIA issued to Liquidia Technologies, Inc.

$LQDA
Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by Liquidia Corporation

Amendment: SEC Form SC 13D/A filed by Liquidia Corporation

Amendment: SEC Form SC 13D/A filed by Liquidia Corporation

SEC Form SC 13G filed by Liquidia Corporation

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for $LQDA

SEC Form SC 13G filed by Liquidia Corporation

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for $LQDA

$LQDA Insider Trading

CFO and COO Kaseta Michael sold $600,132 worth of shares (30,000 units at $20.00), decreasing direct ownership by 7% to 376,412 units (SEC Form 4)

Chief Business Officer Adair Jason sold $8,871 worth of shares (454 units at $19.54), decreasing direct ownership by 0.23% to 193,180 units (SEC Form 4)

Chief Accounting Officer Boyle Dana sold $20,771 worth of shares (1,063 units at $19.54), decreasing direct ownership by 0.57% to 186,105 units (SEC Form 4)

$LQDA Leadership Updates

Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors

Emergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of Directors

Liquidia Corporation Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

$LQDA Insider Purchases

Director Manning Paul B bought $2,999,994 worth of shares (337,078 units at $8.90) (SEC Form 4)

Director Caligan Partners Lp disposed of 3,440,948 shares, sold $1,426,500 worth of shares (150,000 units at $9.51) and bought $1,426,500 worth of shares (150,000 units at $9.51) (SEC Form 4)

Jeffs Roger bought $1,000,001 worth of shares (139,665 units at $7.16), increasing direct ownership by 28% to 640,805 units (SEC Form 4)

$LQDA Financials

Liquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Liquidia Corporation to Report Second Quarter 2025 Financial Results on August 12, 2025

Liquidia Corporation to Report First Quarter 2025 Financial Results on May 8, 2025

$LQDA Press Releases

Liquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Liquidia Corporation to Report Second Quarter 2025 Financial Results on August 12, 2025

Liquidia Receives $50 Million from Healthcare Royalty (HCRx) Following First Commercial Sale of YUTREPIA™

$LQDA SEC Filings

SEC Form 10-Q filed by Liquidia Corporation

Liquidia Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 144 filed by Liquidia Corporation

$LQDA Analyst Ratings

Jefferies resumed coverage on Liquidia Technologies with a new price target

Liquidia Technologies downgraded by Oppenheimer with a new price target

Wells Fargo initiated coverage on Liquidia Technologies with a new price target

$LQDA FDA approvals

FDA Tentative Approval for YUTREPIA issued to Liquidia Technologies, Inc.

$LQDA Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by Liquidia Corporation

Amendment: SEC Form SC 13D/A filed by Liquidia Corporation

Amendment: SEC Form SC 13D/A filed by Liquidia Corporation

Recent Analyst Ratings for
$LQDA

Recent Analyst Ratings for
$LQDA

$LQDA
Insider Trading

$LQDA
Leadership Updates

$LQDA
Insider Purchases

$LQDA
Financials

$LQDA
Press Releases

$LQDA
SEC Filings

$LQDA
Analyst Ratings

$LQDA
FDA approvals

$LQDA
Large Ownership Changes